With the discovery of the EGFR1 receptor, the Her/2 gene and the clinical development of monoclonal antibodies, in September 1998, the FDA approved the first clinical “neutralizing” mab to treat Her/2+ breast cancer, Trastuzumab (Tz), better known publically as Herceptin®. The gene discussed is ERBB2; the disease is breast carcinoma.